Abstract:Summary Background Project Orbis is a global initiative that aims to streamline regulatory review processes across international regulators in the USA, Canada, Australia, UK, Israel, Brazil, Singapore, and Switzerland to bring promising cancer drugs to patients earlier. We explored the clinical benefit, time to regulatory approval and health technology assessment recommendations, reimbursement outcomes, and monthly treatment prices of cancer drugs reviewed through this initiative. Methods For this retrospective, comparative analysis, we identified cancer drug approvals reviewed through Project Orbis in the USA, Canada, and the UK between May 1, 2019, and Nov 1, 2023. Approvals of cancer drugs reviewed Project Orbis were extracted from the Food and Drug Administration (FDA) Oncology Centre of Excellence and all other FDA approvals from the Drugs@FDA database. The co-primary outcomes were time of regulatory review, time from regulatory approval to health technology assessment recommendation (England, Scotland, and Canada), reimbursement outcomes, clinical benefit (defined as median gains in progression-free survival and overall survival) between cancer drug approvals reviewed by Project Orbis and other FDA approval processes, and monthly treatment prices. The Wilcoxon rank-sum and Fisher's Exact tests were used to examine statistical significance between approvals reviewed through Project Orbis and other FDA approvals during the same period. Findings Between May 1, 2019 and Nov 1, 2023, 81 (33%) of 244 cancer drugs approved by the FDA were reviewed through Project Orbis. The median overall survival gains were 4·1 months (IQR 3·3–5·1) compared with 2·7 months (2·1–3·9) for other FDA approvals. Similarly, progression-free survival gains were 2·6 months (IQR 1·7–4·9) for Project Orbis compared with 2·6 months (0·6–5·1) for other FDA approvals. Neither overall survival (p=0·11) nor progression-free survival (p=0·44) gains were significantly different between the two cohorts of approvals. Of the 14 UK Medicines and Healthcare products Regulatory Agency (MHRA) approvals reviewed by the Scottish Medicines Consortium (SMC), the agency gave positive recommendations for all 14 (100%). Of the 15 MHRA approvals reviewed by the National Institute for Health and Care Excellence (NICE), the agency gave positive recommendations for six (40%). Of the 49 approvals reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH), the agency conditionally recommended 44 (90%). The time between regulatory approval to NICE recommendation increased from a median of 137 days (IQR 102–172) in 2021 to 302 days (184–483) in 2023, SMC recommendation increased from 185 days (in 2021 for one drug only) to 368 days (IQR 313–476) in 2023, and CADTH decision increased from 97 days (in 2020 for one drug only) to 202 days (IQR 153–304) in 2023. The median monthly price of approvals reviewed through Project Orbis was US$20 000 per month (IQR 13 000–37 000). Interpretation Clinical outcomes of Project Orbis were no different than other FDA approvals during the same time, and access, after a successful health technology assessment, was considerably delayed or absent, raising questions about whether Project Orbis participation translates into faster patient access to medicines with high clinical benefit and sustainable costs. Although future challenges might benefit from regulatory harmonisation, the advantages are currently unclear. Funding None.

Oncology Drugs: Evolution, Comparative study of Global Drug Regulatory approval process and various measures to improve availability and accessibility

Current Regulatory Status in China of Drugs Withdrawn from the US FDA Accelerated Pathway: Implications for Regulation Globally

Comparative Analysis of New Drugs and Clinical Trial Rules 2019 and its impact on Approval process of Oncology Drugs

Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review

New drug approvals in oncology

Expedited Pathway Insights: Unveiling Oncology and Non-oncology Drug Approvals and Withdrawals of USFDA and EMA

Regulatory approval pathways for anticancer drugs in Japan, the EU and the US

New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil

Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?

Reviewing the Synthesis and Clinical Application of FDA-Approved Anticancer Medications

Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India

[Expedited program and utilization for anticancer drug approval in China and the United States]

Access to anti-cancer drugs in India: is there a need to revise reimbursement policies?

Trends in the approval of cancer therapies by the FDA in the twenty-first century

Balancing speed, science and regulatory requirements in oncology drug development

Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis

Challenges in Anticancer Drug R&D in China

Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing

Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?

Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis